Revela raises £411k for endometriosis ultrasound AI

Revela has raised £411k pre-seed to develop AI that analyses ultrasound for earlier endometriosis diagnosis.

Revela is building software that analyses ultrasound images early in the diagnostic pathway and returns a report for clinicians highlighting possible signs of endometriosis to review. The aim is to shorten the wait between a first GP visit, diagnosis and treatment planning.

Endometriosis is a condition where tissue similar to the womb lining grows outside the uterus, often causing severe pelvic pain, heavy periods and fertility problems. Definitive diagnosis can involve laparoscopy, a keyhole operation using a camera, which contributes to delays in care.

The team plans to use the funding to access larger training datasets and make key hires as it moves towards a first product. Revela says it is developing the technology with patients and clinicians.

Backers of the round include PXN Ventures North of England through its PraeSeed programme, alongside angels from Sixth Wave Ventures, Mint Ventures, Alma Angels and Leeds Angels.

“At Sixth Wave Ventures, we invest in and support truly pioneering start-ups and the exceptional founders behind them through our Sixth Wave angel group,” said Steve Kelly, co-founder and partner at Sixth Wave Ventures. “Revela is a fantastic example — a company tackling a major global women’s health challenge with innovation, scientific rigour, and real-world impact.”

“At Mint Ventures we back women led purpose driven companies who are building products the world has been missing,” said Mint Ventures. “We believe Revela is poised to make a significant difference to women’s health, and we’re excited to be part of their journey.”

Endometriosis affects millions of women globally.